Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; HORIZON Pivotal Fracture Trial. Eastell R, et al. Among authors: lippuner k. J Clin Endocrinol Metab. 2009 Sep;94(9):3215-25. doi: 10.1210/jc.2008-2765. Epub 2009 Jun 30. J Clin Endocrinol Metab. 2009. PMID: 19567517 Free PMC article.
Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis.
Devogelaer JP, Brown JP, Burckhardt P, Meunier PJ, Goemaere S, Lippuner K, Body JJ, Samsioe G, Felsenberg D, Fashola T, Sanna L, Ortmann CE, Trechsel U, Krasnow J, Eriksen EF, Garnero P. Devogelaer JP, et al. Among authors: lippuner k. Osteoporos Int. 2007 Sep;18(9):1211-8. doi: 10.1007/s00198-007-0367-3. Epub 2007 May 22. Osteoporos Int. 2007. PMID: 17516022 Free article. Clinical Trial.
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN; HORIZON investigators. Reid DM, et al. Lancet. 2009 Apr 11;373(9671):1253-63. doi: 10.1016/S0140-6736(09)60250-6. Lancet. 2009. PMID: 19362675 Clinical Trial.
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, Horowitz Z, Kerzberg E, Bianchi G, Kendler D, Leung P, Man Z, Mesenbrink P, Eriksen EF, Black DM; HORIZON Pivotal Fracture Trial. Eastell R, et al. Osteoporos Int. 2010 Jul;21(7):1277-85. doi: 10.1007/s00198-009-1077-9. Epub 2009 Oct 3. Osteoporos Int. 2010. PMID: 19802508 Free PMC article. Clinical Trial.
Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Törring O, Gallagher JC, Farrerons J, Wang A, Franchimont N, San Martin J, Grauer A, McClung M. Boonen S, et al. Among authors: lippuner k. J Clin Endocrinol Metab. 2011 Jun;96(6):1727-36. doi: 10.1210/jc.2010-2784. Epub 2011 Mar 16. J Clin Endocrinol Metab. 2011. PMID: 21411557 Clinical Trial.
[Osteoporosis in Switzerland in 2011: change since 2008].
Rizzoli R, Lippuner K, Kraenzlin M, Birkhaeuser M. Rizzoli R, et al. Among authors: lippuner k. Rev Med Suisse. 2011 Jun 15;7(299):1291-2. Rev Med Suisse. 2011. PMID: 21793417 French. No abstract available.
154 results